MDM2 and B-cell chronic lymphocytic leukemia: SF3B1 mutations in CLL patient samples were found to be associated with resistance to treatment with RG7388 ex vivo, and patients with the wild type for both SF3B1 and TP53 are most likely to benefit from treatment with MDM2 inhibitors [4].